NCT04852822 - Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

July 1, 2024

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Electronic Health Record Review

Medical records are reviewed

Trial Locations (11)

MedStar Georgetown University Hospital, Washington D.C.

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

Ohio State University Comprehensive Cancer Center, Columbus

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

M D Anderson Cancer Center, Houston

Huntsman Cancer Institute/University of Utah, Salt Lake City

City of Hope, Duarte

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

Oregon Health & Sciences University, Portland

Fred Hutch/University of Washington Cancer Consortium, Seattle

Dana-Farber Cancer Institute, Boston